The Emily & Charlie Fund

Bright Blue was created in 2011 because of two very special children of serving WA Police Officers. They were living with a rare form of childhood cancer called neuroblastoma.
Their brave fight against such a devastating disease inspired the creation of a dedicated fund to support research into finding a cure for neuroblastoma.
In 2013 the Emily & Charlie Fund was set up to support the Children’s Cancer Institute Australia in Sydney.
Bright Blue has committed to raise $615,000 by 2017 through the Emily & Charlie Fund to enable new drug discovery in the laboratory.
The Emily & Charlie Fund will support RNA-sequencing on tumour tissue from over 100 children suffering from neuroblastoma.
The data from these experiments will provide invaluable resources for understanding neuroblastoma, not only for the researchers seeking cures at Children’s Cancer Institute Australia but also cancer researchers around the world.
DrTao

Dr Tao Liu – who is heading up the RNA Sequencing Project with a cheque for $135,000 from Bright Blue that was donated in 2014.


The Children’s Cancer Institute

Finding a Cure for Neuroblastoma
sydney instNeuroblastoma is the most common solid tumour in early childhood.
Cancer is the largest killer of children from disease in Australia. Although the survival rate has increased from zero 60 years ago to over 80 per cent today. 625 children are still diagnosed with this disease each year in Australia, with many more in hospital undergoing treatment every day. Of these, sadly, each week on average nearly three children will lose their battle with this awful disease. Neuroblastoma is the most common solid tumour in early childhood, and accounts for 15% of all childhood cancer deaths. Neuroblastomas normally affect children under the age of 5, predominantly infants.
Neuroblastomas arise from immature nerve cells, and can grow in any part of the body where nerves exist.
At present, neuroblastomas are treated as one disease, although we now know there are several subtypes, which behave very differently. Some neuroblastomas grow quickly and kill swiftly, while others do not. Understanding each child’s disease will help us prescribe the drugs that will have the most beneficial effect.
Bright Blue funding has allowed the Children’s Cancer Institute research team, led by Dr Tao Liu, to take ‘snapshots’ of gene expressions within tumours.
We have confirmed the abnormal expression of three genes, one from each of three sub-groups of neuroblastoma patients. In all cases, the genes are ‘overexpressed’, or  over-active, helping the cancers survive and spread.
Children’s Cancer Institute researchers are identifying specific molecules to target these overexpressed genes in order to kill tumour cells and stop cancer spread.
We are confident that it will soon be possible to analyse each child’s neuroblastoma with next generation RNA-sequencing technology, identifying the sub-group to which they belong, according to their tumour’s molecular profile. This will eventually allow clinicians to treat each disease with the right combination of drugs, helping to improve and prolong the lives of children with neuroblastoma.
Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to childhood cancer. Our focus is on translational research, making sure our discoveries are moved from the “bench to the bedside” to develop new and improved treatments for kids with cancer as quickly as possible.
Our partnership with Bright Blue is so important as we strive towards our goal of curing childhood cancer.
It’s not if, it’s when.
1

Online

Click the Donate Now button in the header, you may need to scroll up a little

2

Phone

You can call us on (+61 8) 9222 1724 and donate over the phone

3

Post

We love snailmail! Bright Blue, Police Headquarters, 2 Adelaide Terrace, East Perth 6004

Other Causes

Radio Lollipop believes in the healing power of play – providing smiles and laughter to children at a time when they need it most.
For decades, Interplast has worked on the ground in some of the world’s poorest countries to provide free surgical treatment and facilitate safer, healthier and more sustainable healthcare for communities.